Free prostate-specific antigen in serum is becoming more complex.
about
Twenty Years of PSA: From Prostate Antigen to Tumor MarkerPotential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerClinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancerEmerging PSA-based tests to improve screeningKallikreins as biomarkers for prostate cancerProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesProstate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal BiomarkersA comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressivenessGlycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitorsProstate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples.The role of prostate-specific antigen in the clinical evaluation of prostatic disease.Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome.Applicability of biomarkers in the early diagnosis of prostate cancer.Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men.The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.A Review on the Clinical Utility of PSA in Cancer ProstateBiomarkers for benign prostatic hyperplasia progression.[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening studyTumor markers in prostate cancer I: blood-based markers.Blood biomarkers for prostate cancer detection and prognosis.New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.Screening for prostate cancer: an update.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.Nanobody; an old concept and new vehicle for immunotargeting.From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.Aberrant PSA glycosylation--a sweet predictor of prostate cancer.The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy.The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?Current biomarkers for diagnosing of prostate cancer.Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate CancerSeparation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.Assays for prostate cancer : changing the screening paradigm?The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients.Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
P2860
Q24564782-E80E28CF-2CCF-4710-9882-C7D78C9AFA2BQ26784517-5584A897-6D6F-46D4-9289-FB987E703412Q26824913-F9BFE468-12A7-4B27-B595-D1E545C35413Q26828563-E9F71414-7316-46CA-8656-D6DC36298964Q26862434-E6BE9A37-53EE-47A7-8A0C-FE6D1A21634FQ26865810-21A6CC06-E3EF-4AF3-B383-3508C4AEF68BQ28075610-2294AFA8-904F-4030-A8CD-BA5F0D92EBC7Q33320106-86227C3C-CF65-45D5-A323-BCA58B165886Q33839248-E8E83AC0-CE5E-4A44-A047-B41D0CED417BQ34381513-756F2F6A-EAA3-437F-B4BE-165B638194D5Q34732727-B670BDBE-4DE0-4931-B9CC-97D8E2CF75BAQ35194458-1391E10B-C845-4401-9225-EB4C9ABFE1D8Q35685854-EF6B0DAD-4E1D-4985-AD18-DCE67362D958Q35686079-95E84009-C385-4803-A4EC-A1C536071F4EQ35821838-5B0F07E2-96D9-4519-9200-AAB5CD55B543Q35838386-8F6F67B4-09BD-4C90-8E86-47DAC2E7B44FQ35861497-58823698-4039-4020-A09F-E1D01B3B15D2Q36084063-39A9A80F-A510-49BD-A570-00E549F3A05FQ36122359-38441876-6F5D-4545-9518-9D41F62B1C32Q36509148-E1DD1719-354E-492D-9FE3-24D1A604AC41Q36607766-6FC5FDE9-84D9-4589-A1CA-30C1291B2121Q36895818-9658E8E0-B61E-451E-B1BC-5BCA00C312A9Q36973830-8DCC8F85-8120-4A3B-874E-10B2A55CC02BQ37108081-F4AC654E-2137-4AE5-86C3-6B5D95802A54Q37155070-BB53D976-941F-4721-B487-32153C542A68Q37252155-D993441C-69E3-458C-A1BE-5AF6FE68B816Q37338478-1EB40105-1F8E-49F5-BE99-0CB5A3B75F82Q37738370-6B34F5A7-67A7-4F82-95A4-53E9F5C1838AQ37829737-19D06C2E-6AF4-4A4D-9857-60F3661A8130Q38023597-8FDC71A1-6E2C-4953-8F35-0F6837747482Q38074010-D82340F9-D007-41F2-8DD8-A30AA0E3D997Q38165242-4B401B70-A7E7-4609-9FE6-D010926A027FQ38211603-A38D0175-64DF-4288-96AE-FD40BA52965EQ38584370-4AB7F3BC-523D-4755-B194-9136EDEC063BQ41191641-9DE55C91-7466-400C-8667-F7D8016975EFQ44767389-9E779D55-F359-4115-94E7-A0D43B0DB9C3Q46530327-CA1B09CC-1FD3-45F5-A656-27158B201143Q46569706-85697C7E-8F52-4E3A-928E-73CB3CB63682Q51019666-0E22BEF2-98B8-45F7-9B59-D09FF4090D94
P2860
Free prostate-specific antigen in serum is becoming more complex.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Free prostate-specific antigen in serum is becoming more complex.
@ast
Free prostate-specific antigen in serum is becoming more complex.
@en
Free prostate-specific antigen in serum is becoming more complex.
@nl
type
label
Free prostate-specific antigen in serum is becoming more complex.
@ast
Free prostate-specific antigen in serum is becoming more complex.
@en
Free prostate-specific antigen in serum is becoming more complex.
@nl
prefLabel
Free prostate-specific antigen in serum is becoming more complex.
@ast
Free prostate-specific antigen in serum is becoming more complex.
@en
Free prostate-specific antigen in serum is becoming more complex.
@nl
P2093
P1433
P1476
Free prostate-specific antigen in serum is becoming more complex.
@en
P2093
Harry G Rittenhouse
Leonard S Marks
Stephen D Mikolajczyk
P304
P356
10.1016/S0090-4295(01)01605-3
P407
P577
2002-06-01T00:00:00Z